Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 11355976

Osteosarcoma.

T Philip·J Y Blay·M Brunat-Mentigny·C Carrie·P Chauvot·F Farsi·B Fervers·J C Gentet·F Giammarile·R Kohler·S Mathoulin·L M Patricot·P Thiesse·French National Federation of Cancer (FNCLCC)
View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Bone NeoplasmsFollow-Up StudiesFranceHumansIncidenceMedical OncologyNeoplasm StagingOsteosarcomaQuality Assurance, Health CareGuidelineJournal ArticlePractice Guideline

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

T Philip, J Y Blay, M Brunat-Mentigny, C Carrie, P Chauvot, F Farsi, B Fervers, J C Gentet, F Giammarile, R Kohler, S Mathoulin, L M Patricot, P Thiesse, French National Federation of Cancer (FNCLCC). 2001. Osteosarcoma.. https://doi.org/10.1054/bjoc.2000.1770

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2002

Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone.

Neoplasms have a striking tendency to metastasize or "home" to bone. Hematopoietic cells also home to bone during embryonic development, where evidence points to the chemokine stromal cell-derived factor-1 (SDF-1 or CXCL12; expressed by osteoblasts and endothelial cells) and its receptor (CXCR4) as key elements in these processes. We hypothesized that metastatic prostate carcinomas also use the SDF-1/CXCR4 pathway to localize to the bone. To test this, levels of CXCR4 expression were determined for several human prostate cancer cell lines by reverse transcription-PCR and Western blotting. Positive results were obtained for cell lines derived from malignancies that had spread to bone and marrow. Prostate cancer cells were also observed migrating across bone marrow endothelial cell monolayers in response to SDF-1. In in vitro adhesion assays, pretreatment of the prostate cancer cells with SDF-1 significantly increased their adhesion to osteosarcomas and endothelial cell lines in a dose-dependent manner. Invasion of the cancer cell lines through basement membranes was also supported by SDF-1 and inhibited by antibody to CXCR4. Collectively, these results suggest that prostate cancers and perhaps other neoplasms may use the SDF-1/CXCR4 pathway to spread to bone.

Bone Neoplasms↗
PubMed2002

Localisation of mesenchymal tumours by somatostatin receptor imaging.

Oncogenic osteomalacia, an acquired hypophosphataemic syndrome associated with mesenchymal tumours, is characterised by hypophosphataemia secondary to inappropriate phosphaturia, reduced concentrations of serum calcitriol, and defective bone mineralisation. Removal of these tumours results in complete reversal of these biochemical defects. However, because these tumours are small, slow-growing, and frequently situated in unusual anatomical sites, conventional imaging techniques often fail to detect them. Since mesenchymal tumours express somatostatin receptors, we postulated that somatostatin analogues would be able to detect these tumours. We did Indium-111 labeled pentetreotide imaging in seven patients with oncogenic osteomalacia. In five patients, we identified a mesenchymal tumour, and clinical improvement occurred after tumour resection. Our findings suggest that 111In-pentetreotide imaging effectively detects occult mesenchymal tumours and facilitates surgical treatment of oncogenic osteomalacia.

Bone Neoplasms↗